AALL1521; Ruxolitinib and Chemotherapy for Patients with JAK-Mutant B-ALL

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

7 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This study is testing the safety and effectiveness of adding a targeted therapy (ruxolitinib) to standard chemotherapy for children, adolescents, and young adults with high-risk acute lymphoblastic leukemia with CRLF2 and other JAK pathway mutations.

Eligibility & Criteria

IRB #:
16-012888
Official Title:
AALL1521; A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic Leukemia (INCB 18424-269)
Study Phase:
Phase II
Eligible Age Range:
Any
Gender:
All
Study Categories:
Leader
Sarah K. Tasian

Sarah Tasian, MD